Clever Culture doubles global pharma customer base in Q4 FY26 update
In its Appendix 4C and business update for the quarter ended 30 June 2026 (Q4 FY26), Clever Culture Systems (ASX: CC5) reported that its APAS® Independence platform has now been placed with eight large global pharmaceutical companies, double the four recorded in FY25.
The medical technology company ended the quarter with $1.7 million in cash at 30 June 2026, supplemented by $3.4 million in known and committed inflows expected over the next two quarters. Management described FY26 as the “Land” phase of its “Land and Expand” strategy, with the “Expand” phase set to begin in FY27.
When big ASX news breaks, our subscribers know first
Q4 FY26 sales performance and customer wins
The Company delivered continued growth across its installed base and customer count during the quarter, adding new pharmaceutical relationships that broaden its commercial footprint.
| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Large global pharma customers | 8 | 6 | 4 |
| Instruments installed base | 34 | 30 | 24 |
| New orders received in quarter | 3 | 3 | 1 |
| Instruments under evaluation | 3 | 2 | 1 |
New pharmaceutical placements
CSL Behring placed a 5-year lease order for an APAS® Independence instrument during the quarter. The instrument was installed at the company’s Broadmeadow facility in Melbourne in June 2026, where an initial evaluation will assess suitability for broader standardisation across its manufacturing network.
A second new large global pharmaceutical customer, whose name was withheld for commercial reasons, will commence a 6-month paid evaluation of the technology. Similar to the CSL placement, the evaluation will assess performance against agreed criteria for potential use across its global sterile drug manufacturing network.
The Company also received an order from a smaller US-based manufacturer, representing a single-site sale. Management noted this reflects growing awareness of the APAS® technology and an expansion of the addressable market beyond the targeted top-30 global pharmaceutical manufacturers.
Investors exploring the strategic significance of the CSL placement will find our full explainer on the CSL Behring lease order covers the multi-site deployment pathway in detail, including how CSL’s own language around broader standardisation frames this evaluation as a global network assessment rather than a standalone instrument purchase.
For investors, the quarter added breadth of customer relationships that the Company expects to seed future multi-instrument expansion.
Understanding APAS® Independence and the “Land and Expand” model
APAS® Independence uses artificial intelligence and machine-learning software to automate the imaging, analysis and interpretation of microbiology culture plates. According to the Company, it is the only US FDA-cleared artificial intelligence technology for automated culture plate reading.
The technology serves two primary markets: reading environmental monitoring culture plates in pharmaceutical manufacturing, and acting as an in vitro diagnostic for infectious diseases in clinical laboratories. Thermo Fisher Scientific, Inc is the exclusive distributor of APAS® Independence to clinical customers in the United States and selected countries in Europe.
The “Land and Expand” model involves securing a customer with an initial instrument (the “Land” phase), then scaling deployments across that customer’s manufacturing network (the “Expand” phase). For investors, the appeal lies in recurring high-margin software licences combined with the multiplier effect as each customer adds instruments over time.
Financial position and cash runway
The Company ended the quarter with $1.7 million in cash ($1,687k) at 30 June 2026. Total net cash outflow for the quarter was $0.3 million.
Net cash outflows from operating and investing activities totalled $1.7 million, which included $0.6 million in cash inflows from customers offset by $2.3 million in expenditures. Financing activities generated net inflows of $1.4 million, largely from $1.5 million in proceeds received under a short-term debt agreement, with a further $0.1 million received on 1 July 2026, taking the total to $1.6 million.
Short-term debt facility terms
The Company disclosed the following terms for the short-term debt facility:
-
Total facility of $1,600,000, which is unsecured.
-
Interest based on an annual rate of 10%.
-
16,000,000 unlisted options issued on 1 July 2026, expiring 30 June 2028. The exercise price is stated inconsistently in the source: the business update cites $0.033 while the Appendix 4C cites $0.33. This figure should be treated with caution pending clarification.
-
$1,680,000 due for repayment on 31 December 2026, inclusive of interest.
The Company considers this short-term debt to be a “capital efficient means of funding the business” during the Land and Expand phase.
Expected inflows
The Company anticipates at least $3.4 million in known or committed inflows over the next two quarters, comprising:
-
$1.8 million in receivables at 30 June 2026, including the US single-site sale and a non-refundable evaluation deposit.
-
$0.7 million estimated FY26 Research and Development Tax Incentive claim.
-
$0.9 million in committed inflows from customers.
Up to $2.6 million of this is expected in the first quarter, supporting near-term working capital alongside anticipated new sales. Cashflows for the quarter also included related party payments of $125,000 to Directors, comprising the Managing Director’s salary and Non-Executive Directors’ fees.
FY27 outlook and the pipeline opportunity
Having established a footprint across eight large global pharmaceutical customers, the Company enters FY27 with a broader base from which to pursue increased instrument sales, recurring software revenue and validation-services revenue.
Brent Barnes, CEO and Managing Director
“FY26 saw an effective ‘Land’ campaign, doubling the number of large global pharmaceutical manufacturers with APAS® Independence… We are excited to be moving into the sales expansion phase starting in FY27 and beyond.”
The Company estimates that its eight existing large global pharmaceutical customers alone represent a potential medium-term opportunity of up to 100 instrument sales, equivalent to approximately $50 million in upfront sales and $10 million in annual recurring revenue. A further 80 instrument opportunities are estimated across the new qualified customer pipeline. Current Annual Recurring Revenue, predominantly high-margin software licences, exceeds $1.3 million per annum.
Building services and market presence
In June, the Company recruited a dedicated UK-based validation-services resource to support customers through evaluation and validation towards routine use, which is expected to contribute to future revenues as sales grow.
The Company also hosted its inaugural APAS® Discovery Day at AstraZeneca’s centre of excellence facility in Macclesfield, United Kingdom. The event brought together customers spanning 10 countries, with presentations from AstraZeneca, Pfizer and CCS. It coincided with the first in-person meeting of the APAS® Expert User Group, which currently has six large global pharmaceutical customers as members expected to meet 3-4 times annually.
Looking ahead, the Company will showcase APAS® Independence at four major conferences across Australia, Europe, the United Kingdom and the United States in October and November 2026. An investor conference call is scheduled for 11.30am AEST on Monday, 3 August 2026, hosted by CEO and Managing Director Brent Barnes.
Don’t Miss the Next Healthcare Breakout
Big News Blast delivers FREE breaking ASX healthcare and biotech news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already staying ahead of the market. Click the “Free Alerts” button at Big News Blast to get the next market-moving announcement the moment it drops.